Fortress Biotech Analyst Price Targets

Wall Street analyst price targets and consensus rating for Fortress Biotech (FBIO).

Price Target Range — 8 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$13Upside to Avg. PT+552.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Feb 23, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$17
Aug 21, 2025	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$26→$17
Mar 11, 2025	Roth MKM	Jason Wittes	PT Raise	Buy	$15→$16
Nov 18, 2024	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$24→$26
Jul 19, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$24
Jun 20, 2024	Cantor Fitzgerald	Jennifer Kim	Maintained	Overweight	—
May 16, 2024	Roth MKM	Jason Wittes	Maintained	Buy	$10
Mar 19, 2024	Alliance Global Partners	—	Initiate	Buy	$5
Mar 15, 2024	Roth MKM	Jason Wittes	Reinstates	Buy	$10
Nov 29, 2023	Roth MKM	Scott Henry	PT Cut	Buy	$30→$15

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $17 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Fortress Biotech, Lowers Price Target to $17

HC Wainwright & Co. analyst Joseph Pantginis maintains Fortress Biotech (NASDAQ:FBIO) with a Buy and lowers the price target from $26 to $17.

Benzinga Newsdesk

PRO
Roth MKM Reiterates Buy on Fortress Biotech, Raises Price Target to $16

Roth MKM analyst Jason Wittes reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and raises the price target from $15 to $16.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Fortress Biotech, Raises Price Target to $26

HC Wainwright & Co. analyst Joseph Pantginis maintains Fortress Biotech (NASDAQ:FBIO) with a Buy and raises the price target from $24 to $26.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $24 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $24 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Fortress Biotech

Cantor Fitzgerald analyst Jennifer Kim reiterates Fortress Biotech (NASDAQ:FBIO) with a Overweight.

Benzinga Newsdesk

Fortress Biotech Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Fortress Biotech Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Fortress Biotech, Lowers Price Target to $17

PRO
Roth MKM Reiterates Buy on Fortress Biotech, Raises Price Target to $16

PRO
HC Wainwright & Co. Maintains Buy on Fortress Biotech, Raises Price Target to $26

PRO
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $24 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on Fortress Biotech

People Also Watch

People Also Watch

Fortress Biotech Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Fortress Biotech Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target

PROHC Wainwright & Co. Maintains Buy on Fortress Biotech, Lowers Price Target to $17

PRORoth MKM Reiterates Buy on Fortress Biotech, Raises Price Target to $16

PROHC Wainwright & Co. Maintains Buy on Fortress Biotech, Raises Price Target to $26

PROHC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $24 Price Target

PROCantor Fitzgerald Reiterates Overweight on Fortress Biotech

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Fortress Biotech, Lowers Price Target to $17

PRO
Roth MKM Reiterates Buy on Fortress Biotech, Raises Price Target to $16

PRO
HC Wainwright & Co. Maintains Buy on Fortress Biotech, Raises Price Target to $26

PRO
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $24 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on Fortress Biotech